通过一种新型的双重响应性丹德里默-N-乙半氨酸合物持续和步骤释放药物
Ozgul Gok1, Anjali Sharma1, Siva P Kambhampati1
1Center for Nanomedicine, Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States.
Biomacromolecules
|July 3, 2025
概括
这项研究引入了一种使用聚胺胺 (PAMAM) 树枝体的新型纳米药物,以将抗炎药物N-乙囊 (NAC) 输送到大脑. 创新的设计确保了治疗神经炎症的持续和有针对性的药物释放.
科学领域:
- 纳米医学是一种纳米医学.
- 神经科学是一个神经科学.
- 药物运输 药物运输 药物运输
背景情况:
- 聚胺胺 (PAMAM) 树突体显示出针对大脑的潜力,因为它们能够穿过受伤的血脑屏障.
- 开发用于神经炎症疾病的有效药物输送系统仍然是一个重大挑战.
研究的目的:
- 利用第四代PAMAM树状体开发一种新型的针对大脑的纳米药物.
- 为抗炎药物N-乙半氨酸 (NAC) 创建持续释放系统.
- 研究该系统在治疗与神经炎症相关的中枢神经系统 (CNS) 疾病方面的潜力.
主要方法:
- 通过和二硫化键 (D() 设计,将N-乙半氨酸 (NAC) 二元体与PAMAM树脂体结合.
- 研究由环境pH和氧化还原潜力触发的逐步药物释放.
- 在体外评估结合物的非毒性行为,细胞吸收和对内毒素激活的微质细胞的治疗作用.
主要成果:
- 经过D() ((NACssNAC) 结合体的演示,逐步释放的药物对pH和氧化还原潜力有反应.
- 光标记的合物证实了无毒行为和依赖时间的细胞吸收.
- 与对照组相比,在激活的微质细胞中观察到增强的抗炎和抗氧化作用.
结论:
- 开发的基于PAMAM树突分子的纳米药物 (DNACNAC合物) 显示出针对性大脑输送的巨大潜力.
- 这个平台为长期治疗神经炎症相关的中枢神经系统疾病提供了一个有希望的方法.
- 逐步释放药物机制提高了治疗疗效和向性治疗.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...